

Part VI: Summary of the risk management plan

Summary of risk management plan for [Invented name] 20 mg/ml + 5 mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*)

This is a summary of the RMP for [Invented name] 20 mg/ml + 5mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*).

The RMP details important risks of [Invented name] 20 mg/ml + 5 mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*), how these risks can be minimised, and how more information will be obtained about [Invented name] 20 mg/ml + 5 mg/ml eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*)'s risks and uncertainties (missing information).

[Invented name] 20 mg/ml + 5 mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*)'s SmPC and its PL give essential information to healthcare professionals and patients on how [Invented name] 20 mg/ml + 5 mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*) should be used.

Important new concerns or changes to the current ones will be included in updates of [Invented name] 20 mg/ml + 5 mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*)'s RMP.

I. The medicine and what it is used for

[Invented name] 20 mg/ml + 5 mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*) is authorised for the treatment of elevated intra-ocular pressure (IOP) in patients with open-angle glaucoma or pseudoexfoliative glaucoma when topical beta-blocker monotherapy is not sufficient.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of [Invented name] 20 mg/ml + 5 mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*), together with measures to minimise such risks and the proposed studies for learning more about the product's risks are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the PL and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine*

pharmacovigilance activities.

If important information that may affect the safe use of [Invented name] 20 mg/ml + 5 mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*) is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of [Invented name] 20 mg/ml + 5 mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*) are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken.

Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of [Invented name] 20 mg/ml + 5 mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*). Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine):

List of important risks and missing information	
Important identified risks	• None
Important potential risks	• None
Missing information	• None

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of [Invented name] 20 mg/ml + 5 mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*).

II. C.2 Other studies in post-authorisation development plan

There are no studies required for [Invented name] 20 mg/ml + 5 mg/ml, eye drops, solution (*dorzolamide hydrochloride* and *timolol maleate*).